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Anmol Kumar, Kärt Varendi, Johan Peränen and Jaan-Olle Andressoo*Abstract
Brain-derived neurotrophic factor (BDNF) regulates multiple biological processes ranging from central nervous system
development and function to neuroinflammation and myogenic differentiation and repair. While coordination of BDNF
levels is central in determining the biological outcome, mechanisms involved in controlling BDNF levels are not fully
understood. Here we find that both short (BDNF-S) and long (BDNF-L) BDNF 3’UTR isoforms contain conserved
adenylate- and uridylate rich elements (AREs) that may serve as binding sites for RNA-binding proteins (ARE-BPs). We
demonstrate that ARE-BPs tristetraprolin (TTP) and its family members butyrate response factor 1 (BRF1) and 2 (BRF2)
negatively regulate expression from both BDNF-S and BDNF-L containing transcripts in several cell-lines and that
interaction between TTP and AU-rich region in proximal 5’ end of BDNF 3’UTR is direct. In line with the above,
endogenous BDNF mRNA co-immunoprecipitates with endogenous TTP in differentiated mouse myoblast C2C12
cells and TTP overexpression destabilizes BDNF-S containing transcript. Finally, RNAi-mediated knock-down of TTP
increases the levels of endogenous BDNF protein in C2C12 cells. Our findings uncover TTP as a novel regulator of
BDNF assisting future studies in different physiological and pathological contexts.
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BDNF is involved in a wide range of developmental,
functional and pathological processes in the central
nervous system (CNS) (Nagahara and Tuszynski 2011;
Kirschenbaum and Goldman 1995; Cohen-Cory et al. 2010;
Bamji et al. 2006; Nieto et al. 2013; Mu et al. 1999).
Outside the CNS, processes regulated by BDNF include
inflammation (Uchida et al. 2013; Lin et al. 2011;
Gomes et al. 2013; Amoureux et al. 2008; Luhder et al.
2013), development of neuromuscular junctions (Je et al.
2012), muscle regeneration after injury (Clow and
Jasmin 2010) and myogenic differentiation (Mousavi and
Jasmin 2006).
Precise regulation of BDNF levels is critical in determining
the biological outcome. Reduction of BDNF levels by 50% in
BDNF knock-out heterozygous mice is associated with a
range of phenotypes in the CNS (Lyons et al. 1999;
Dluzen et al. 2002; Abidin et al. 2006; Abidin et al. 2008).
On the other hand, a 2-fold elevation in endogenous
BDNF by the suppression of miR-206, a direct negative
regulator of BDNF levels, alleviates disease phenotype
in a mouse model of Alzheimer’s disease (Lee et al. 2012).
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in any medium, provided the original work is plevels is believed to be required to allow myogenic
differentiation (Mousavi and Jasmin 2006). However,
despite the biological and potential clinical relevance,
mechanisms controlling BDNF levels are not fully
understood.
As a result of alternative polyadenylation, BDNF
transcripts have either a long (BDNF-L, 2891 nt) or
short (BDNF-S, 350 nt) 3’UTR (Timmusk et al. 1993).
The ratio between transcripts containing BDNF-L and
BDNF-S varies with BDNF-L levels ranging between
20-50% in different tissues and cells-lines (Timmusk et al.
1994; Miura et al. 2012). Alternative 3’UTR isoforms allow
cells to differentially regulate expression from transcripts
containing long or short 3’UTR.
Elements within the 3’UTR that control mRNA stability
enable to adjust the expression of important regulatory
proteins, including neurotrophic factors. Adenylate-
and uridylate (AU)-rich elements (AREs) are typically
50–150 bp areas in the 3’UTR that serve as binding
sites for trans-acting ARE binding proteins (ARE-BPs)
which either stabilize or destabilize transcripts (Xu et al.
1997; Barreau et al. 2005). Although the exact consensus
sequence of AREs is not in depth understood, AREs are
often highlighted by high AU content and concomitant
presence of AUUUA pentamers (Chen and Shyu 1995;n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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proximately 8% of the human transcriptome contains
AREs. However, relatively few AREs are experimentally
verified as functional targets of ARE-BPs (Barreau et al.
2005; Bakheet et al. 2006; Barrett et al. 2012; Apponi et al.
2011; Gruber et al. 2011; Pascale and Govoni 2012).
ARE-BPs tristetraprolin (TTP), butyrate response factor 1
(BRF1) and 2 (BRF2) form the TIS11/TTP family of
ARE-BPs that target mRNAs for rapid degradation by
binding to AREs (Hudson et al. 2004; Brooks and
Blackshear 2013; Sanduja et al. 2011). TIS11/TTP
family proteins are central regulators of the expres-
sion of inflammatory cytokines and several oncogenes
(Hudson et al. 2004; Brooks and Blackshear 2013;
Sanduja et al. 2011). Whether TIS11/TTP family could
control the expression levels of neurotrophic factors, such
as BDNF, has remained unknown.
In the current study, we used publicly available in
silico tools to search for conserved AREs in BDNF-L and
BDNF-S, and look for ARE-BPs co-expressed with BDNF
in sites with known BDNF function. We find that ARE-BPs
TTP, BRF1 and BRF2, but not ELAVL1 or ELAVL2, inhibit
expression from luciferase reporters containing BDNF-L
and BDNF-S, and that AUF1 has a mild inhibitory effect in
the same assay. Using electrophoretic mobility shift
assay (EMSA), we demonstrate a direct interaction
between the 5’ region of BDNF-S and recombinant
TTP protein and find that endogenous BDNF mRNA
co-immunoprecipitates with TTP. In line with the
above, over-expression of TTP destabilizes transcript
containing BDNF-S. Finally, we show that siRNA-mediated
down-regulation of TTP during myogenic differentiation
of mouse myoblast C2C12 cells leads to increased BDNF
protein expression. Altogether, our findings suggest
that TTP is a new post-transcriptional regulator of BDNF
expression.
Materials and methods
Cell culture
Human Embryonic Kidney 293 (HEK-293), Chinese Hamster
Ovary (CHO), HeLa and C2C12 cells were cultured at 5%
CO2 and 37°C in growth medium (GM) containing
Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen/
Gibco) supplemented with 10% fetal bovine serum
(FBS; SV30160, Thermo Fisher Scientific) and 100 μg/ml
Normocin (InvivoGen). Cells were kept at sub-confluent
density and split one day before plating for an experiment.
C2C12 wells were seeded to 6-well plates pre-coated
with 0.1% gelatin. Myogenic differentiation of C2C12
mouse skeletal myoblast cells was induced by replacing
growth medium with differentiation medium (DM)
containing DMEM supplemented with 2% horse serum
(HS; B15-021, PAA) (Miura et al. 2012) and 100 μg/ml
Normocin.Constructs and cloning
Gateway® pcDNA™-DEST40 vectors encoding for
ARE-binding proteins for expression in mammalian
cells were obtained from Genome Biology Unit (Institute
of Biotechnology, University of Helsinki, Finland). Long
and short BDNF 3’UTR-s (BDNF-L and BDNF-S) were
amplified from BAC clone RP24-149 F11 (RPCI-24:
Mus musculus (C57BL/6 J male) BAC library; BACPAC
Resources) using primers with XbaI sites (Additional file 1:
Table S1), and cloned into XbaI site in pGL4.13 vector
downstream Firefly luciferase gene (E6681,Promega) and in
XbaI site in pGL4.73 vector downstream Renilla luciferase
gene (E6911,Promega). Similarly, U1 and U2 fragments
were amplified with primers containing XbaI sites
(Additional file 1: Table S1) from BDNF long 3’ UTR se-
quence and cloned into pGL4.73 vector (E6911,Promega)
and Bluescript KS + (Stratagene). All constructs were
verified by sequencing. In addition, ARE-BP protein
expression from various ARE-BP encoding Gateway®
pcDNA™-DEST40 vectors in HEK-293 cells was verified
using Western blotting (Additional file 1: Figure S1a). We
also assessed whether the C-terminal tag (V5 or His)
encoded by pcDNA™-DEST40 vectors has an impact on
RBP activity in luciferase assay and found no difference
between the tested tagged and non-tagged ARE-BP activity
(Additional file 1: Figure S1b and see below).
Luciferase reporter assay
For luciferase reporter assay, cells were seeded to 96-well
plates (pre-coated with 0.1% gelatin for HEK-293 cells),
plating density per well was 15,000 (HEK-293 and CHO
cells) and 10,000 (HeLa cells) in a volume of 100 μl one
day before transfection. Reporter plasmids in 10:1 ratio
(100 ng Luc-BDNF-L, Luc-BDNF-S, Luc-U1 and Luc-U2,
if not indicated otherwise) and 10 ng either pGL4.73
[hRluc/SV40] or pGL4.13 [luc2/SV40]) as internal controls
were co-transfected per well on 96 well plate to normalize
the luciferase signal in dual luciferase assay. BDNF-L/
BDNF-S transcript ratio in HEK-293 cells transfected
with BDNF-L is 60/40, as assessed by QPCR analysis.
Transfections were done according to standard protocol
recommended for Lipofectamine 2000 (11668–019,
Invitrogen). Growth medium was replaced with fresh
cell culture medium after 3–4 hours after transfection.
Luciferase assay was performed with Dual-Luciferase®
Reporter Assay System (E1960, Promega) as recommended
by the manufacturer. Briefly, cells were lysed 24 hours after
the transfection with Passive Lysis Buffer (E1960, Promega).
Plates were either stored at −80°C or analyzed immediately
with Dual-Luciferase Reporter Assay reagents. Results from
each experiment were normalized to controls from the
same experiment. Data for each figure panel was collected
from a set of several experiments where constructs
indicated on the figure were present in each experiment.
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containing reporter gene expression is observed in all
experiments, but the strength of inhibition on reporter
gene expression varies up to about 1.7 fold between
different sets of experiments. The reason for variance
between different experimental sets is not known, but
likely reflects normal variance in cell-culture experiments.
Each experiment contained 3–4 replicates per construct/
treatment and was repeated 2–8 times as specified in the
figure legends.
Recombinant TTP protein production
Human TTP open reading frame was cloned into a
T7lac based vector containing a His-tag (Peranen et al.
1996). The vector was transformed into BL21 (DE3) cells
(Novagen), and the protein was expressed in the presence of
IPTG (isopropyl β-D-thiogalactoside) for 4 h at 24°C. The
cells were lysed in buffer A (20 mM Tris HCl, pH 8.0, 0.5%
Triton X-100, 10 mM b-mercaptoethanol, 0.4 mM PMSF)
by sonication. Then, NaCl and imidazole were added to a
final concentration of 0.5 and 0.02 M, respectively. After
centrifugation (15,000 × g for 15 min at 4°C) the supernatant
was passed through a 0.45 μm filter. The His-TTP protein
was purified by the HisTrap kit according to the manufac-
turer (GE Healthcare). Buffer B (50 mM Tris–HCl (pH 8.0),
150 mM NaCl, 0.5 mM EDTA, 1 mM DTT) exchange was
done by using a PD-10 column (GE Healthcare). His-tag
was cleaved from His-TTP by AcTEV (Invitrogen). The
His-tag and AcTEV were removed by application to a
HiTrap Chelating column and TTP was collected from the
flow-through. TTP was concentrated using an Amicon
Ultra-4 filter device (Millipore). Aliquots of TTP were snap
frozen in liquid nitrogen and stored at −80°C.
Electrophoretic Mobility Shift Assay (EMSA)
Depending on the orientation of U1 and U2 fragments,
T7 or T3 RNA polymerase was used to synthesize RNA
probes in vitro. RNA 3' End Biotinylation Kit (20160,
Thermo Scientific Pierce) was used to label RNA probe at
the 3’ end according to manufacturer’s protocol. Biotin
labeling efficiency was assessed by dot plot as recom-
mended by the manufacturer. Biotin-labeled RNA probes
were diluted (5-10x) based on labeling efficiency obtained
by dot plot assay. Diluted RNA probes were incubated
with different concentrations of purified TTP protein at
room temperature for 30 minutes in 20 μl reaction
mixture containing 10 mM HEPES (pH 7.3), 40 mM
KCl, 3 mM MgCl2, 2 mM DTT, 5% glycerol and
2 mg/ml tRNA. The reaction was mixed with 1X REMSA
loading buffer (Thermo Scientific Pierce) and run for
2 hours in 6% native polyacrylamide gel at 130 V. The
bands were transferred to positively charged nylon mem-
brane (Roche) and UV cross-linked at 120 mJ/cm2 for
1 min. The detection of biotin-labeled RNA probeswas done using LightShift Chemiluminescent RNA EMSA
Kit (20158, Thermo Scientific Pierce) according to
manufacturer’s protocol.
RNA isolations and quantitative real-time PCR
RNA from C2C12 cells was isolated using either TRI
reagent (TR 118, Molecular Research Center Inc.) or
Trizol (15596–018, Ambion) according to protocol
provided by the manufacturers. RNA samples were treated
with Turbo DNA-free DNase (AM1907, Invitrogen) to
remove DNA. cDNA synthesis using random hexamer
primers in a final volume of 20 μl was performed using
Transcriptor First Stand cDNA synthesis kit (04896866001,
Roche) as recommended by manufacturer. Quantitative
real-time PCR (RT-PCR) was done with Lightcycler
480 real-time PCR system (Roche Diagnostics) using
Lightcycler 480 SYBR Green I Master Mix. Three
replicate wells were run for each sample. Primers used for
RT-PCR are indicated in Additional file 1: Table S1.
RNA interference
SMART pool siGENOME mouse Zfp36 (TTP) siRNA
(M-041045-01-0005,Thermo Scientific) and siGENOME
Non-Targeting siRNA Pools (D-001206-13, Thermo
Scientific) were transfected to C2C12 cells 50–75
pmol each using Lipofectamine® RNAiMAX Transfection
Reagent (13778030, Invitrogen) as recommended by the
manufacturer.
Western blot
For detection of RBP expression in cell-lines, samples
were run on 12% acrylamide gel for 1 hour and blotted
to Hybond-ECL membrane (G1492720, GE Healthcare).
The membrane was incubated in blocking solution
(5% Non-fat milk, TBS, 0.1% Tween) for 30 minutes
and incubated in anti-V5 Mouse Monoclonal Antibody
(R960-25, Invitrogen) at 1:6000 dilution in the blocking
solution for 50 minutes. The membrane was washed and
incubated in polyclonal goat-anti-mouse HRP-conjugated
secondary antibody (P0447, Dako) at 1:2000 dilution in
the blocking solution for 50 minutes. Pierce ECL Western
Blotting Substrate (32106, Thermo Scientific Pierce) was
used for signal detection according to manufacturer’s
instructions.
Enzyme-linked immunosorbent assay (ELISA)
Differentiation medium (DM) from C2C12 cells was
collected at day 5 as described in the experimental
plan in Figure 1a and centrifuged at 2000 rpm at +4°C for
2 minutes to remove cell debris. BDNF protein levels in
the DM were measured using BDNF Emax® ImmunoAssay
System (G7611, Promega) according to manufacturer’s
protocol. BDNF levels were normalized to total protein
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Figure 1 AUUUA- motifs in mouse BDNF 3’ UTR and their conservation among vertebrates. a. Schematic diagram of BDNF mRNA products
with long (BDNF-L) and short (BDNF-S) 3’UTRs. AUUUA sequences, often serving as ARE-BP binding motifs within AU-rich elements (AREs) are
indicated with black triangles, AREs UAUUUAU are indicated with up arrowheads, black box denotes BDNF coding sequence (Source: AREsite and
AREscore). mRNA-s transcribed from luciferase reporter constructs (grey boxes) containing BDNF-L, BDNF-S, U1, U2 and ARE-rich fragment from
TNFα 3’UTR. The positions of U1 and U2 (see below) are indicated above Luc-BDNF-S. b. Scheme depicting conservation of AUUUA sequences
among vertebrates. UAUUUAU motifs are underlined and in bold.
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according to manufacturer’s recommendations.
RNA immunoprecipitation (RNA-IP) assay
RNA-IP was performed as described previously (Ishmael
et al. 2008). Briefly, differentiated C2C12 cells in six-well
plate (CellStar) were lysed in 250 μl of polysome lysis
buffer (100 mM KCL, 5 mM MgCl2, 10 mM HEPES
(pH 7.0), 0.5% Nonidet P-40, 1 mM DTT, 100 U/ml
RNaseOUT (Invitrogen), 0.2% vanadyl-ribonucleoside com-
plex (New England Biolabs), Protease Inhibitor Cocktail
(Roche)) and centrifuged at 12000 rpm for 15 minutes
at 4°C. A/G agarose beads (Santa Cruz) were precoated
with 10 μg of antibody against TTP or normal rabbit IgG
(Santa Cruz). 100 μl of cell lysate was mixed withprecoated A/G agarose beads in 900 μl of NT-2 buffer
(50 mM Tris (pH 7.4), 150 mM NaCl, 1 mM MgCl2, 0.5%
Nonidet P-40) supplemented with 1 mM DTT, 100 U/ml
RNaseOUT, 0.2% vanadyl-ribonucleoside complex and
20 mM EDTA and incubated for 2 hours at RT. Washed
beads were incubated with NT-2 buffer supplemented
with 0.1% SDS and 0.5 mg/ml Proteinase K at 55°C for
30 minutes. RNA was isolated and real time quantitative
PCR was performed as described above.
RNA turnover assay
HEK-293 cells were transfected as described above with
Luc-BDNF-S, empty vector (pDEST 40) or TTP encoding
plasmids. After 24 hours 1 μg/ml of Actinomycin D
(A 1410, Sigma Aldrich) was added to the medium. Cells
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and semi-quantitative PCR was performed using primers
indicated in Additional file 1: Table S1.
Statistical analysis
For luciferase assay, data points from experiments within
one experimental set (experimental set is defined as re-
peated experiments containing the same set of constructs)
were averaged and used for statistical calculations. For
other experiments, data was averaged from repeated
experiments and used for statistical calculations. Error
bars of graphs represent standard deviations (±SD). Data
was analyzed with 2-tailed Student’s t-test assuming
unequal variance. The level of significance was set at
p < 0.01 unless otherwise indicated. Experiments were
repeated 2–8 times with 2–4 replicates per experiment as
indicated in specific figure legends.
Results
In silico prediction of ARE sites in the BDNF 3’UTR
Using publically available web tools AREsite (Gruber et al.
2011) (http://rna.tbi.univie.ac.at/cgi-bin/AREsite.cgi) and
AREscore (Spasic et al. 2012) (http://arescore.dkfz.de/are-
score.pl), we identified five conserved AUUUA motifs in
the BDNF 3’UTR flanked by AU-rich sequences (Figure 1,
Additional file 1: Figure S2). Two of the five AUUUA
motifs were present in BDNF-S, while three AUUUA motifs0
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(Hudson et al. 2004; Brooks and Blackshear 2013) and
one of the core 7-mer motifs is located in BDNF-S (Figure 1
Additional file 1: Figure S2).
TTP family ARE binding proteins inhibit expression of a
luciferase reporter containing BDNF-L and BDNF-S
To analyze the biological importance of the in silico
identified ARE motifs in BDNF 3’UTR, we cloned mouse
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ARE binding proteins forming the TTP family - TTP,
BRF1 and BRF2, but not ELAVL1 or ELAVL2, significantly
inhibit expression of luciferase reporter containing
BDNF-L in the human embryonic kidney 293 (HEK-293)
cells, while AUF1 had a marginal effect (Figure 2a). Next
we compared the effects of ARE-BP-s on BDNF-S and
BDNF-L in the same reporter assay and found that the
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studied the effect of TTP on the stability of a transcript
containing BDNF-S upon transcriptional inhibition using
actinomycin D. In line with results from luciferase assay,
TTP overexpression destabilized BDNF-S containing
transcript (Figure 2c). To test whether the observed
inhibition by TTP family members is also observed in
other cell-lines from different species we performed the
luciferase assay in Chinese hamster ovary (CHO) cells and
in Hela cells. TTP and BRF1 suppressed reporter gene
expression in both cell-lines (Additional file 1: Figure S3a).
TTP interacts with 5’ proximal end of BDNF-S without the
requirement for AUUUA motif
BDNF-S contains a proximal AUUUA site and a distal
UAUUUAU site (Figure 3a). Both sites are conserved
among vertebrates (Figure 1b) and may serve as binding site
for ARE-BPs (Hudson et al. 2004; Brooks and Blackshear
2013). However, within the AU-rich region, (U)AUUUA(U)
sequence may also be dispensable for RBP, including for
TTP binding (Chen et al. 1994; Lopez de Silanes et al. 2004;
Lopez de Silanes et al. 2005). To further characterize the
suppressive effect of TTP on BDNF-S, we cloned the 5’
proximal end of the BDNF 3’UTR containing both
conserved AUUUA site-s (designated as U1, Figure 3a) and
the adjacent 3’UTR fragment (designated as U2, Figure 3a)
into luciferase reporter construct as above. The overall
AU-content of U1 and U2 fragments is comparable
(Additional file 1: Figure S4). As a positive control
for TTP inhibition in the luciferase reporter system
we used a well-characterized target of inhibition byFo
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wer TTP encoding plasmid concentration (10 ng), suggesting different
y TTP, a 140 bp ARE-rich fragment from TNF-alpha 3’UTR (Luc-TNF-ARE)
periment. Error bars indicate SD, ***p < 0.001. c. Electrophoretic mobility
n (50 ng and 100 ng) and no band shift of RNA probe U2 under the same
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http://www.springerplus.com/content/3/1/502To discriminate between these two options, we stud-
ied the requirement of proximal AUUUA site, the
distal UAUUUAU site and the necessity of both sites
together in U1 (Figure 3a) for suppression by TTP.
We generated constructs where the proximal AUUUA
site (Luc-BDNFSmut1), distal UAUUUAU site (Luc-
BDNFSmut2) and both (Luc-BDNFSmut1-2) AUUUA
sequences were replaced with UAUAU. Changing either
one or both AUUUA sequences to UAUAU did not affect
the ability of TTP to inhibit BDNF-S (Additional file 1:
Figure S3c), suggesting that BDNF-S falls into the class of
3’UTR-s where AUUUA elements are dispensable for RBP
function (Chen et al. 1994; Lopez de Silanes et al. 2004;
Lopez de Silanes et al. 2005).
TTP interacts with BDNF mRNA and regulates
endogenous BDNF levels in myogenic C2C12 cells
TTP is acutely and transiently induced within 30 minutes
following skeletal muscle injury in satellite cells,
which give rise to myoblasts (Sachidanandan et al. 2002;
Apponi et al. 2011). However, targets of TTP regulation
upon muscle differentiation are unknown. On the other
hand, BDNF is expressed in skeletal muscle satellite cells
and down-regulation of BDNF levels is believed to beb
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medium at day 5. N = 3 experiments with two repeats per experiment, **p< 0.0required to allow myogenic differentiation of myoblasts
into myotubes (Mousavi and Jasmin 2006; Miura et al.
2012;). Our results suggest that TTP may suppress
BDNF levels by directly interacting with its 3’UTR.
To gain further insight into this, we first studied the
expression levels of TTP, BRF1 and BRF2 in differen-
tiating C2C12 cells, an established model of muscle
differentiation (Burattini et al. 2004). Confirming and ex-
tending the earlier findings, we found that TTP, but not
BRF1 or BRF2, is upregulated upon differentiation in
C2C12 cells (Figure 4a-b). Next, we performed RNA-
immunoprecipitation in differentiating C2C12 cells using
antibodies against TTP and found that endogenous TTP
co-immunoprecipitates with endogenous BDNF mRNA
(Figure 4c). Finally, we tested the effect of RNAi knock-
down of endogenous TTP (Figure 4d) on endogenous
BDNF levels in C2C12 cells, and found concomitant
upregulation of BDNF protein levels (Figure 4e).
Discussion
Recently, 3’UTRs have emerged as an important site of
gene expression regulation by binding of micro-RNAs
(miRs) and RBPs. Long and conserved 3’UTRs that
provide a binding platform for miRs and RBPs are especially0
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(Barrett et al. 2012). During the last two years, several miRs
have been shown to directly interact with BDNF 3’UTR and
regulate its expression(Miura et al. 2012; Lee et al. 2012;
Varendi et al. 2014). However, how RNA binding proteins
impact BDNF expression has largely remained unexplored.
Microarray analysis of primary fibroblasts derived from
TTP deficient mice revealed BDNF mRNA among ca 250
elevated mRNAs (Lai et al. 2006), suggesting that BDNF is
either directly or indirectly regulated by TTP. Our results
suggest that the suppressive effect of TTP on BDNF mRNA
level is direct.
BDNF and TTP family members are co-expressed in
many tissues, suggesting that the observed regulation may
be involved in controlling a range of biological processes
from CNS function to inflammation and muscle differenti-
ation. That fine-tuning of BDNF levels via its 3’UTR has
physiological and clinical importance is illustrated by
a recent study by Lee et al., where anti-miR based knock-
down of miR-206, a negative regulator of BDNF, increased
endogenous BDNF levels and alleviated Alzheimer’s
disease in a mouse model (Lee et al. 2012).
So far only one ARE-BP, ELAVL4, is reported to
impact BDNF mRNA stability by specifically stabilizing the
BDNF-L but not the BDNF-S isoform (Allen et al. 2013).
BDNF-L makes up 20-50% of BDNF transcripts in the
CNS (Timmusk et al. 1994). We find that TTP binds to
the 5’ proximal end (U1) of the BDNF 3’UTR and
suppresses expression from both BDNF-S and BDNF-L to
a comparable extent. This suggests that in BDNF 3’UTR,
either U1 is the only binding platform for TTP, that
binding of TTP distal to U1 has no additive effect on
suppression, or that in BDNF-L only the distal binding
site is accessible for TTP. Future studies will help to
discriminate between these options.
TTP was discovered and has been characterized as an
important regulator of inflammation (Sanduja et al. 2011;
Taylor et al. 1996; Carballo et al. 1998; Brooks and
Blackshear 2013). BDNF is the first neurotrophic factor
identified as a target of TTP regulation. Interestingly,
similar to TTP, BDNF regulates inflammatory processes
including microglial activation and neuropathic pain
(Uchida et al. 2013; Lin et al. 2011; Gomes et al. 2013;
Amoureux et al. 2008), as well as neuroimmunological
disease (Luhder et al. 2013). How TTP-mediated regulation
of BDNF impacts the inflammatory processes remains to
be explored.
Interestingly, as a rule, ARE-BP proteins share target
mRNA-s. For an example GM-CSF, TNF-alpha and c-fos
are shared targets of AUF1, ELAVL1 and TTP, see
(Barreau et al. 2005) for review. We find that BDNF
3'UTR is directly regulated by TTP but the effect of
AUF1 and ELAVL1 is either minor or absent. Therefore,
further analysis of BDNF 3’UTR involving bioinformaticsand laboratory techniques may enable to disclose which
sequence/structure components in the BDNF 3’UTR
underlie its specificity for TTP.
Taken together, co-expression of BDNF and TTP
family members in various cell types and tissues suggests
potential relevance of the interaction between TTP family
and BDNF 3’UTR isoforms in different physiological
and pathological processes. We hope our work facilitates
future studies addressing the physiological and therapeutic
potential of TTP/BDNF interaction in various organ
systems.
Additional file
Additional file 1: Table S1. List of cloning and Q-PCR primers. Table S2.
BDNF is co-expressed with ARE-BPs in various tissues with known BDNF
function. Figure S1. a. Western blotting using antibodies against V5-tag
showing that ARE-BP encoding constructs used in the study result in
proteins with expected sizes. In addition, constructs used in this study were
sequenced (see also MM). b. C-terminal tag (V5 or His) has no effect on TTP,
ELAVL1 and ELVAL2 ability to modulate expression from reporter construct
containing Luc-BDNF-L. N = 2 experiments with 4 repeats per experiment,
***p < 0.001. Error bars indicate SD. Figure S2. Mouse Bdnf 3’UTR sequence.
Location of AUUUA motifs is indicated by red, UAUUUAU motifs are red in
italics; the sequence of BDNF-S is bold and underlined. Figure S3. a. Similar
to HEK293 cells (Figure 3), inhibitory effect of TTP and BRF1 on BDNF-L
expression is observed in Hela cells and in Chinese hamster ovary cells
(CHO). N = 1-2 experiments with 4 repeats per experiment, error bars
indicate SD, ***p < 0.001, **p < 0.01. b. Similar to HEK293 cells (Figure 4b),
low concentration of TTP encoding plasmid (0.5 ng/96-well plate well) has
inhibitory effect on TNF-ARE and U1 but not on U2 in CHO cells. N = 3
experiments with 3–4 repeats per experiment, ***p < 0.001. c. Mutation in
5’, 3’ or both AUUUA sites present in BDNF-S has no effect on TTP-mediated
inhibition on expression from Luc-BDNF-S reporter construct. N = 2
experiments with 3–4 repeats per experiment, ***p < 0.001. Error bars
indicate SD on all graphs. Figure S4. AU percent in BDNF 3’ UTR fragments
U1, U2 and in TNFα 3’UTR ARE fragment.
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